Search

Your search keyword '"Ezekowitz, Justin A."' showing total 2,323 results
Start Over Author "Ezekowitz, Justin A."
2,323 results on '"Ezekowitz, Justin A."'

9. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Author

Borlaug, Barry A., Kitzman, Dalane W., Davies, Melanie J., Rasmussen, Søren, Barros, Eric, Butler, Javed, Einfeldt, Mette Nygaard, Hovingh, G. Kees, Møller, Daniél Vega, Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N.

Published
2023
Full Text
View/download PDF

20. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Author

Butler, Javed, Shah, Sanjiv J, Petrie, Mark C, Borlaug, Barry A, Abildstrøm, Steen Z, Davies, Melanie J, Hovingh, G Kees, Kitzman, Dalane W, Møller, Daniél Vega, Verma, Subodh, Einfeldt, Mette Nygaard, Lindegaard, Marie L, Rasmussen, Søren, Abhayaratna, Walter, Ahmed, Fozia Z, Ben-Gal, Tuvia, Chopra, Vijay, Ezekowitz, Justin A, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovský, Vojtěch, Merkely, Bela, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, Sharma, Kavita, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N

Published
2024
Full Text
View/download PDF

23. Incidence of Hospital Admission of Out-of-Hospital Cardiac Arrest Patients, and Their Outcomes, in Canada, 2013-2017

Author

Grunau, Brian, Christenson, Jim, Fordyce, Christopher, Blanchard, Ian, Lazarenko, Gerald, DeCaen, Allan, Van Diepen, Sean, Ezekowitz, Justin, Bakal, Jeff, Brooks-Lim, Elizabeth, Davis, Philip, Olszynski, Paul, Cheskes, Sheldon, Huyer, Dirk, Cunningham, Kris, Dainty, Katie, Ko, Dennis, Tan, Nigel, Lawler, Patrick R., Vaillancourt, Christian, Charette, Manya, Green, Martin, Udupa, Sharmila, Segal, Eli, Demontigny, Luc, Brian Potter, Theresa Choisi, Sapp, John, Goldstein, Judah, Jensen, Jan, Carter, Alix, Bowes, Matthew, Connors, Sean, Duffett, Stephen, Metcalfe, Brian, Avis, Simon, Sibley, Aaron, Grubic, Nicholas, Allan, Katherine S., Ghamarian, Ehsan, Lin, Steve, Lebovic, Gerald, and Dorian, Paul

Published
2024
Full Text
View/download PDF

24. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial

Author

WESTERHOUT, CYNTHIA M., RATHWELL, SARAH, ANSTROM, KEVIN J., HERNANDEZ, ADRIAN F., PONIKOWSKI, PIOTR, EZEKOWITZ, JUSTIN A., VOORS, ADRIAAN A., FELKER, G. MICHAEL, BAKAL, JEFFREY A., BLAUSTEIN, ROBERT O., NKULIKIYINKA, RICHARD, O'CONNOR, CHRISTOPHER M., and ARMSTRONG, PAUL W.

Published
2024
Full Text
View/download PDF

26. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial

Author

Harrington, Josephine, Mentz, Robert J., Rockhold, Frank W., Garg, Jyotsna, Butler, Javed, De Pasquale, Carmine G., Ezekowitz, Justin A., Lewis, Gregory D., O'Meara, Eileen, Ponikowski, Piotr, Troughton, Richard W., Wong, Yee Weng, Adamczyk, Robert, Blackman, Nicole, and Hernandez, Adrian F.

Published
2023
Full Text
View/download PDF

28. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

Author

Butler, Javed, Abildstrøm, Steen Z., Borlaug, Barry A., Davies, Melanie J., Kitzman, Dalane W., Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter P., Chopra, Vijay, Ezekowitz, Justin A., Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, von Lewinski, Dirk, Wolf, Dennis, Altschul, Rebecca L., Rasmussen, Søren, and Kosiborod, Mikhail N.

Published
2023
Full Text
View/download PDF

29. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

Author

Tromp, Jasper, Ezekowitz, Justin A., Ouwerkerk, Wouter, Chandramouli, Chanchal, Yiu, Kai Hang, Angermann, Christiane E., Dahlstrom, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V., Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Collins, Sean P., Filippatos, Gerasimos, Cleland, John G.F., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

30. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial

Author

Ezekowitz, Justin, Colin-Ramirez, Eloisa, Ross, Heather, Escobedo, Jorge, Macdonald, Peter, Troughton, Richard, Saldarriaga, Clara, Alemayehu, Wendimagegn, McAlister, Finlay, Arcand, JoAnne, Atherton, John, Doughty, Robert, Gupta, Milan, Howlett, Jonathan, Jaffer, Shahin, Lavoie, Andrea, Lund, Mayanna, Marwick, Thomas, McKelvie, Robert, Moe, Gordon, Pandey, A. Shekhar, Porepa, Liane, Rajda, Miroslaw, Rheault, Haunnah, Singh, Jitendra, Toma, Mustafa, Virani, Sean, Zieroth, Shelley, Ezekowitz, Justin A, McAlister, Finlay A, and Pandey, A Shekhar

Published
2022
Full Text
View/download PDF

33. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

Author

Pitt, Bertram, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Komajda, Michel, Testani, Jeffrey M., Wilcox, Christopher S., Ponikowski, Piotr, Lopes, Renato D., Ezekowitz, Justin A., Sun, Franklin, Davies, Michael J., Verma, Subodh, Kosiborod, Mikhail N., and Steg, Ph. Gabriel

Published
2023
Full Text
View/download PDF

36. Comparative Effectiveness of Primary Prevention Implantable Cardioverter‐Defibrillators in Older Heart Failure Patients With Diabetes Mellitus

Author

Sharma, Abhinav, Wu, Jingjing, Xu, Haolin, Hernandez, Adrian, Felker, G Michael, Al‐Khatib, Sana, Green, Jennifer, Matsouaka, Roland, Fonarow, Gregg C, Singh, Jagmeet P, Heidenreich, Paul A, Ezekowitz, Justin A, and DeVore, Adam

Subjects
Heart Disease, Health Services, Prevention, Aging, Diabetes, Cardiovascular, Comparative Effectiveness Research, Clinical Research, Metabolic and endocrine, Good Health and Well Being, Age Factors, Aged, Aged, 80 and over, Centers for Medicare and Medicaid Services, U.S., Death, Sudden, Cardiac, Defibrillators, Implantable, Diabetes Mellitus, Electric Countershock, Female, Heart Failure, Humans, Male, Primary Prevention, Registries, Risk Assessment, Risk Factors, Stroke Volume, Time Factors, Treatment Outcome, United States, Ventricular Function, Left, arrhythmia, diabetes mellitus, implantable cardioverter-defibrillator, sudden cardiac death, implantable cardioverter‐defibrillator, Cardiorespiratory Medicine and Haematology
Abstract

Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative effectiveness of ICD placement in patients with diabetes mellitus and HF with reduced ejection fraction. Methods and Results Data were obtained from the Get With the Guidelines-Health Failure registry, linked with claims from the Centers for Medicare & Medicaid Services. We used a Cox proportional hazards model censored at 5 years with propensity score matching. Of the 17 186 patients with HF with reduced ejection fraction from the Centers for Medicare & Medicaid Services claims database (6540 with diabetes mellitus; 38%), 1677 (646 with diabetes mellitus; 39%) received an ICD during their index HF hospitalization or were prescribed an ICD at discharge. Patients with diabetes mellitus and an ICD (n=646), as compared with those without an ICD (n=1031), were more likely to be younger (74 versus 78 years of age) and have coronary artery disease (68% versus 60%). After propensity matching, ICD use among patients with diabetes mellitus, as compared with those without an ICD, was associated with a reduced risk of all-cause mortality at 5 years after HF discharge (54% versus 59%; multivariable hazard ratio, 0.73; 95% CI, 0.64-0.82; P

Published
2020

37. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author

Anker, Stefan D, Butler, Javed, Khan, Muhammad Shahzeb, Abraham, William T, Bauersachs, Johann, Bocchi, Edimar, Bozkurt, Biykem, Braunwald, Eugene, Chopra, Vijay K, Cleland, John G, Ezekowitz, Justin, Filippatos, Gerasimos, Friede, Tim, Hernandez, Adrian F, Lam, Carolyn SP, Lindenfeld, JoAnn, McMurray, John JV, Mehra, Mandeep, Metra, Marco, Packer, Milton, Pieske, Burkert, Pocock, Stuart J, Ponikowski, Piotr, Rosano, Giuseppe MC, Teerlink, John R, Tsutsui, Hiroyuki, Van Veldhuisen, Dirk J, Verma, Subodh, Voors, Adriaan A, Wittes, Janet, Zannad, Faiez, Zhang, Jian, Seferovic, Petar, and Coats, Andrew JS

Subjects
Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Prevention, Good Health and Well Being, Betacoronavirus, COVID-19, Clinical Trials as Topic, Coronavirus Infections, Europe, Heart Failure, Humans, Informed Consent, Pandemics, Patient Selection, Pneumonia, Viral, Research Design, SARS-CoV-2, Heart failure, Clinical trials, Coronavirus, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas.

Published
2020

38. Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure

Author

Sharma, Abhinav, Wu, Jingjing, Ezekowitz, Justin A, Felker, Gary Michael, Udell, Jacob A, Heidenreich, Paul A, Fonarow, Gregg C, Mahaffey, Kenneth W, Hernandez, Adrian F, and DeVore, Adam D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Heart Disease, Cardiovascular, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Benzhydryl Compounds, Canagliflozin, Diabetes Mellitus, Type 2, Female, Glucosides, Heart Failure, Humans, Hypoglycemic Agents, Inpatients, Male, Registries, Retrospective Studies, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome, diabetes mellitus type 2, eligibility, heart failure, SGLT-2 inhbitors, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsSodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outcome trials: empagliflozin in EMPA-REG OUTCOME and canagliflozin in CANVAS. The scope of eligibility for SGLT-2 inhibitors (empagliflozin and canagliflozin) among patients with type 2 DM and HF, based on clinical trial criteria and current US Food and Drug Administration (FDA) labelling criteria, remains unknown.Methods and resultsUsing data from the US Get With The Guidelines (GWTG)-Heart Failure registry, we evaluated the proportion of patients with DM and HF eligible for SGLT-2 inhibitor therapy based on the clinical trial criteria and the US FDA labelling criteria. The GWTG-HF registry is a quality improvement registry of patients admitted in hospital with HF in the USA. We included GWTG-HF registry participants meeting eligibility criteria hospitalized between August 2014 and 30 June 2017 from sites fully participating in the registry. The initial inclusion time point reflects when both drugs had FDA approval. Among the 139 317 patients (out of 407 317) with DM hospitalized with HF (in 460 hospitals; 2014 to 2017), the median age was 71 years, 47% (n = 65 685) were female, and 43% (n = 59 973) had HF with reduced ejection fraction. Overall, 43% (n = 59 943) were eligible for the EMPA-REG OUTCOME trial, 45% (n = 62 818) were eligible for the CANVAS trial, and 34% (n = 47 747) of patients were eligible for either SGLT-2 inhibitors based on the FDA labelling criteria. Among the FDA-eligible patients, 91.5% (n = 43 708) were eligible for either the EMPA-REG OUTCOME trial or the CANVAS trial. Patients who were FDA eligible, compared with those who were not, were younger (70.0 vs. 72.0 years of age), more likely to be male (57.7 vs. 50.3%), and had less burden of co-morbidities.ConclusionsThe majority of patients with DM who are hospitalized with HF are not eligible for SGLT-2 inhibitor therapies. Ongoing studies evaluating the safety and efficacy of SGLT-2 inhibitors among patients with HF may potentially broaden the population that may benefit from these therapies.

Published
2020

40. Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, Canada

Author

Behrouzi, Bahar, Sivaswamy, Atul, Chu, Anna, Ferreira-Legere, Laura E., Abdel-Qadir, Husam, Atzema, Clare L., Jackevicius, Cynthia, Kapral, Moira K., Wijeysundera, Harindra C., Farkouh, Michael E., Ross, Heather J., Ha, Andrew C.T., Tadrous, Mina, Paterson, Michael, Gershon, Andrea S., Džavík, Vladimír, Fang, Jiming, Kaul, Padma, van Diepen, Sean, Goodman, Shaun G., Ezekowitz, Justin A., Bainey, Kevin R., Ko, Dennis T., Austin, Peter C., McAlister, Finlay A., Lee, Douglas S., and Udell, Jacob A.

Published
2023
Full Text
View/download PDF

43. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy

Author

DEFILIPPI, CHRISTOPHER R., ALEMAYEHU, WENDIMAGEGN G., VOORS, ADRIAAN A., KAYE, DAVID, BLAUSTEIN, ROBERT O., BUTLER, JAVED, EZEKOWITZ, JUSTIN A., HERNANDEZ, ADRIAN F., LAM, CAROLYN S.P., ROESSIG, LOTHAR, SELIGER, STEPHEN, SHAH, PALAK, WESTERHOUT, CYNTHIA M., ARMSTRONG, PAUL W., and O'CONNOR, CHRISTOPHER M.

Published
2023
Full Text
View/download PDF

47. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction

Author

Cochran, Jesse D., Yura, Yoshimitsu, Thel, Mark C., Doviak, Heather, Polizio, Ariel H., Arai, Yuka, Arai, Yohei, Horitani, Keita, Park, Eunbee, Chavkin, Nicholas W., Kour, Anupreet, Sano, Soichi, Mahajan, Nitin, Evans, Megan, Huba, Mahalia, Naya, Nadia Martinez, Sun, Hanna, Ban, Young Ho, Hirschi, Karen K., Toldo, Stefano, Abbate, Antonio, Druley, Todd E., Ruberg, Frederick L., Maurer, Mathew S., Ezekowitz, Justin A., Dyck, Jason R.B., and Walsh, Kenneth

Published
2023
Full Text
View/download PDF

49. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial

Author

Ezekowitz, Justin A., McMullan, Ciaran J., Westerhout, Cynthia M., Piña, Ileana L., Lopez-Sendon, Jose, Anstrom, Kevin J., Hernandez, Adrian F., Lam, Carolyn S.P., O’Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Koglin, Joerg, Armstrong, Paul W., and Butler, Javed

Published
2023
Full Text
View/download PDF

50. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy

Author

Januzzi, James L., Jr, Butler, Javed, Del Prato, Stefano, Ezekowitz, Justin A., Ibrahim, Nasrien E., Lam, Carolyn S.P., Lewis, Gregory D., Marwick, Thomas H., Rosenstock, Julio, Tang, W.H. Wilson, Zannad, Faiez, Lawson, Francesca, Perfetti, Riccardo, and Urbinati, Alessia

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results